The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Seagen (Inst)
CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
 
Eunice S. Wang
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Seagen; Sigma-Tau; Spectrum Pharmaceuticals
Speakers' Bureau - Incyte
Research Funding - Immunogen (Inst)
 
Lionel Adés
No Relationships to Disclose
 
Amir Tahmasb Fathi
Honoraria - Agios; Baxalta; Merck; Seagen; Tolero Pharmaceuticals
Research Funding - Celgene (Inst); Exelixis (Inst); Seagen (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Agios
 
Karl A Kreuzer
Research Funding - Seagen (Inst)
 
Megan Marie O'Meara
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Shang-Ying Liang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Farhad Ravandi
Honoraria - Seagen
Consulting or Advisory Role - Seagen
Research Funding - Seagen (Inst)